Homologous recombination (HR) is a major DNA repair pathway that is deficient in a small subset of cancers. The best characterized of these are cancers associated with a germline or acquired mutation in the breast cancer 1 and 2 tumour suppressor genes (BRCA1 and BRCA2 respectively). HR-deficient cells rely on non-HR DNA repair pathways that are dependent on poly (ADP-ribose) polymerase (PARP), so that inhibition of PARP is an Achilles' heel in these cancers. PARP inhibitors have emerged as an effective therapeutic strategy in HR-deficient tumours (1), and several are currently in clinical trials in ovarian, BRCA-mutated breast cancer, and other cancers.
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In spite of the promise that this class of therapies holds, it is increasingly apparent that tumours may possess intrinsic and/or acquired resistance mechanisms involving restoration of HR, presenting a pressing clinical problem (2-5). Thus, strategies targeting HR may potentially confer or restore PARP inhibitor sensitivity. One such strategy involves the drug dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9 (6). Additionally, we have recently demonstrated that dinaciclib is the most potent inhibitor of CDK12 known thus far, and therefore a transcriptional regulator of HR genes (7-10).
We comprehensively examined the combination of dinaciclib and PARP inhibitors, such as veliparib and olaparib, in preclinical models of triple-negative breast cancer (TNBC), including BRCA wild-type cells, BRCA-mutated cells, and patient-derived xenograft (PDX) models of primary and acquired resistance to PARP inhibition (10) . First, pathway analyses demonstrated that the genes down-regulated by dinaciclib in BRCA wild-type TNBC cells were significantly enriched for those involved in HR repair and DNA damage-sensing, including BRCA1 and RAD51. Consequently, dinaciclib disrupted HR repair in cell-based assays, and the IC50 of veliparib was consistently reduced in the presence of dinaciclib in a panel of BRCA wild-type TNBC cell lines. These results were phenocopied by CRISPR/Cas9-mediated knockout of CDK12 in TNBC cells. Importantly, dinaciclib had minimal effects on the cell cycle of breast cancer cells. These data point to a pivotal role of dinaciclib in disrupting HR, mediated through inhibition of CDK12.
In light of this, we hypothesized that BRCA-mutated TNBC with acquired PARP inhibitor resistance might be resensitized to PARP inhibition with dinaciclib. Using a BRCA1-mutated cell line with acquired resistance after exposure to increasing PARP inhibitor concentrations in vitro, and an in vivo TNBC PDX model derived from a BRCA2 carrier, who had progressed on olaparib and cisplatin, we demonstrated that the combined dinaciclib and veliparib therapy restored tumour growth inhibition.
PARP inhibitor resistance, and a TNBC PDX model derived from a 185delAG BRCA1 carrier, whose tumor demonstrated primary resistance to olaparib. Despite BRCA1 mutation, these cell lines and the PDX demonstrated residual HR activity, accounting for de novo resistance. Dinaciclib resulted in a concentration-dependent reduction of RAD51 Recombinase (RAD51), BRCA1, and BRCA2 protein levels, and similarly sensitized tumour cells to PARP inhibition both in vitro and in vivo. Dinaciclib suppressed expression of RAD51 and formation of RAD51 foci, and in combination with PARP inhibition, caused greater induction of H2A histone family, member X (-H2AX) foci compared with PARP inhibitor alone.
Finally, we modeled the in vivo activity of these treatments in a PDX model derived from a patient with an early-stage TNBC harboring a somatic R1443* BRCA1 mutation. In this model, veliparib monotherapy produced prolonged stable disease. In contrast, combined dinaciclib and veliparib resulted in substantial and durable tumor regression.
Importantly, histological analyses of the bone marrow and organs harvested at the end of the experiment (156 days) from combination-treated mice revealed no abnormalities, and minimal -H2AX staining, indicating that the treatment combination was well tolerated and selective for tumour cells. It is possible that dinaciclib-mediated inhibition of CDKs 1 and 2 induced greater cell cycle arrest in non-transformed cells, protecting them from PARP inhibitor-mediated cytotoxicity. This produces the critically important therapeutic window for this combination strategy.
Residual HR or restoration of HR plays a major role in de novo and acquired PARP in inhibitor resistance, and may occur by varied and complex mechanisms. The ability of CDK12 inhibition to transcriptionally downregulate multiple components of the HR pathway suggests that it may be therapeutically effective as a sensitizer to PARP inhibitors even when the precise mechanism of HR restoration is unknown. Our work has demonstrated the efficacy of combined CDK12 and PARP inhibition in multiple BRCA-mutated models in reversing PARP inhibitor resistance, and conferring improved therapeutic efficacy in PARP inhibitor-sensitive TNBC. The latter finding is important, as even in this setting, tumour regression is rarely complete and durable with PARP inhibitors alone.
This therapeutic strategy may also have broader implications beyond reversing PARP inhibitor resistance in BRCA-mutated tumours. In the setting of breast cancer, there is a larger subset of BRCA1/2 wild-type tumours; combinatorial strategies that render tumour cells HR-deficient have the potential to sensitize these tumours to PARP inhibitors, and therefore increase the utility of PARP inhibitors to a larger patient population beyond germline BRCA1/2 carriers.
Building on our findings, a phase 1 trial of dinaciclib and veliparib is currently in progress (NCT01434316). Once recommended phase 2 treatment doses are determined, the trial will enroll expansion cohorts assessing preliminary activity in both BRCA wild-type and BRCA-mutated TNBCs, including those that are PARP inhibitor resistant and PARP inhibitor-naive.
